# TelyRx Q3 Revenue Climbs to $23.1 Million as Net Loss Widens

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/52122
Published: 2026-11-09T06:58:57.000Z
Updated: 2026-11-09T06:58:57.000Z
Section: Business

> Revenue increased from $12.337 million a year earlier, while basic and diluted loss per share narrowed to $0.06 even as net loss grew.

TelyRx Holdings Inc. generated $23.078 million in third-quarter 2026 revenue as its net loss widened to $2.829 million, giving investors a mixed picture of growth and profitability at the health care and digital pharmacy platform.

Revenue for the three months ended Sept. 30 rose from $12.337 million in the same quarter of 2025. Net loss increased from $1.058 million. Gross profit climbed to $13.775 million from $6.886 million, while gross margin expanded to 60% from 56%.

Basic and diluted loss per share were both $0.06, compared with $0.10 a year earlier. TelyRx’s unaudited interim statements were prepared under International Accounting Standard 34 and International Financial Reporting Standards, and calculate loss per share under IAS 33. They present the $0.06 figure as loss per share.

The company’s Q3 revenue included $17.4 million from recurring customers and $5.7 million from new customers. TelyRx linked its wider operating loss to $1 million in noncash stock-based compensation, increased advertising and marketing investment, and higher spending on infrastructure, personnel and operations.

TelyRx recorded a $1.277 million adjusted EBITDA loss in Q3, compared with a $3.201 million loss in Q2 2026 and a $351,000 loss in Q3 2025. Adjusted EBITDA is a non-IFRS measure of earnings before interest, taxes, depreciation and amortization, modified by specified adjustments. Because it includes those adjustments, it differs from the net loss in the company’s interim statements.

“Our third quarter reflects the discipline we bring to growing this business. We held revenue steady while narrowing our Adjusted EBITDA loss by more than half from the prior quarter,” TelyRx President and CEO Vanessa Slowey said.

The unaudited interim statements were approved for issuance Nov. 5, the date of the company’s Q3 announcement. All amounts are in U.S. dollars.